-
NPS Focus: Designer Benzodiazepines
Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive Substances (NPS) in mid-2020, which includes designer benzodiazepines,…
-
Expansion of Urine Behavioral Health Drug Testing, AcuRiseID™
Aegis Sciences Corporation, a leading healthcare company that provides innovative medication adherence testing, is pleased to announce the expansion of…
-
Increase in Drug Overdoses Due to Synthetic Opioids During the COVID-19 Pandemic
The challenges of the COVID-19 pandemic have continued to affect populations across the world in numerous ways. Finding a solution to the pandemic has…
-
What Did My Patient Actually Take? An Overview of Dextromethorphan/Levorphanol Results
Accurate interpretation of dextromethorphan/levorphanol results should take into account the patient’s prescription and over-the-counter (OTC) drug regimen…
-
Drug-Drug Interactions (DDI) amidst the Pandemic and Opportunities for Objective DDI Monitoring via Oral Fluid Testing
The Coronavirus Disease 19 (COVID-19) pandemic has introduced many different challenges to the world this year. Economic, technologic, and healthcare issues…
-
COVID-19 and Its Impact on Persons with Mental Illness and Substance Use
The COVID-19 pandemic has brought significant challenges to both healthcare systems and public health. Social distancing, disruption of healthcare services,…
-
Emerging Data on Novel Psychoactive Substances and Clinical Effects
Emerging Data on Novel Psychoactive Substances and Clinical Effects Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive…
